

XXXXX XXXXX

Do Blood group and Sickle cell trait protect against placental malaria?

ARNOLD T. LUUSE¹⁻³, HUSEINI ALIDU³, MAWUSI ADEPA MAWULI^{2,4},
ABDUL-RAHMAN MUBARAK^{1,2,4} and BEN GYAN^{2,5}

¹West Africa Center for Cell Biology of Infectious Pathogens; ²Department of Biochemistry Cell and Molecular Biology, University of Ghana, Accra; ³School of Allied Health Sciences, University of Health and Allied Sciences, Ho; ⁴Department of Pathology, University of Ghana Medical School, College of Health Sciences, University of Ghana, Korle-Bu, Accra, Ghana; ⁵Department of Immunology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra

DOI: 10.4081/jphia.2024.2817

Abstract. Blood group O is reported to confer some degree of protection from severe malaria in endemic setting. This protection is believed to be due to reduced and smaller rosette formation in people of blood group O which can easily be cleared by the host immune system. Also, sickle cell trait (HbAS) is reported to disrupt the adhesion of infected erythrocytes to microvascular endothelial walls, which could protect pregnant women from placental malaria. We determined the association between HbAS and ABO blood group, and placental malaria amongst pregnant women of all parities. The study enrolled 221 pregnant women. Peripheral blood samples were taken for malaria smears, ABO blood grouping and haemoglobin (Hb) electrophoresis. A structured questionnaire was used to age, bed net usage, and the number of Sulphadoxine-pyrimethamine (SP) doses taken by a pregnant woman. Two hundred and twenty-one (221) pregnant women were enrolled and out of this number, 110 (49.8%) were primiparae and 111 (50.2%) multiparae, with a mean age of 23.7±5.2. Placental malaria (PM) prevalence by PCR detection was 19.4% (43/221). Of those who were malaria positive 58.1% (25/43) were primiparae. Primiparae who are of blood group O were more susceptible to PM [P=0.04, (OR); 2.85, 95% (CI), 1.12-9.01]. But sickle cell trait did not reduce the prevalence of PM [P=0.84 (OR); 0.92, 95% (CI), 0.43-1.99]. Non-blood group O primiparae women were protected against placental malaria. This could be why some primiparae women are protected from PM, just like multiparae women.

Introduction

Malaria during pregnancy can be detrimental to the pregnant woman and the unborn child. It may result in maternal death, low birth weight or still births (1-3).

There are many factors that have been linked to this poor outcome of pregnancy, which include host factors (4) and *P. falciparum* factors (5). One of the major complication of malaria in pregnancy (MIP) is when parasitized erythrocyte sequester in the placenta (6,7). These *Plasmodium falciparum* infected erythrocyte sequester in the placenta using a unique protein called VAR2CSA protein on their surfaces (8-10). These sequestrations alters placenta function (11,12) by impeding maternal-foetal exchange of nutrients, often resulting in adverse pregnancy outcomes (10,13).

Some hemoglobinopathies contribute to reduced host's susceptibility to malaria (14,15), specifically, sickle cell trait (HbAS, HbSC and HbSS genotypes) and blood group O are reported to protect against malaria (16-18). The mechanisms by which sickle cell traits, protect against malaria are still not clear, though it is reported to interfere with the transport of parasite antigen (PfEMP1) outside the red blood cell (RBCs) (14,15). This mitigates parasite sequestration on tissues, and hence reduces disease severity (19).

The protective role of human blood grouping against malaria infections have also been reported by many studies (20-22). Some reported group O to resist against malaria infections due to reduced resetting (23,24). But current reports on ABO blood group's ability to protect against placental *P. falciparum* infections are conflicting. Therefore, further understanding of the role of ABO blood group in the pathogenesis and outcome of placental malaria is essential. Therefore, we investigated the association between HbAS and ABO blood group and placental malaria amongst pregnant women of all parities.

Materials and methods

Study site. The study was conducted in the Hohoe Municipal Hospital, in the Hohoe Municipality in the Volta Region

Correspondence to: Huseini Alidu, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana
E-mail: hwalidu@uhas.edu.gh

Key words: malaria, PCR, electrophoresis, placental, gravidae

of Ghana. The population of this Municipality is 167,016, according to the 2010 Population and Housing Census. Malaria cases are reported throughout the year in the municipality, but the peak of cases occur in the wet seasons (April to July and September to November) with an average prevalence of 20.3% (25).

Study design, ethics and sample collection. The study was a cross sectional study conducted between July 2017 and February 2019 where 221 pregnant women were enrolled. Peripheral blood samples (4 ml) were drawn into EDTA tubes, and used for malaria smears, ABO blood grouping, dried blood blots for malaria parasites identification using PCR and electrophoresis for Hb phenotyping. A structured questionnaire was used to capture age, gravidae and bed net usage. Baby weight extracted from labour ward records and Hb levels were measured using HaemoCue 301 machine. All pregnant women who failed to sign the informed consent forms were excluded from the study. Infant birth weight and other maternal data were extracted from the ward register.

Ethics approval and consent to participate. Ethical approval was obtained from the ethics committee of the Ghana Health Service (GHS-ERC: 06103117) and Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana (NMIMR-IRB CPN 077116.17). Participation was voluntary and written informed consent was obtained from participants.

Haemoglobin electrophoresis: Normal saline (5 ml) was added to 0.5 ml RBCs and centrifuged for 3 minutes, the supernatant was discarded and the process was repeated to thoroughly wash off the plasma, leaving RBC pellets. These pellets were lysed by adding 1 ml of distilled water, which was left to stand for about 5 min. About 500 ml of electrophoresis buffer TEB (0.12 M Tris, 5 mM EDTA, 15 mM boric acid, pH 8.9) was put in the electrophoresis tank compartments. Cellulose acetate strips were placed in the electrophoresis tank, and about 5 μ l of haemolysate were loaded into the corresponding designated sample areas. Controls from patients with known haemoglobinopathies were included for each run.

DNA extractions. Blood blots were made from peripheral blood samples, dried and stored in a ziplock plastic bag and kept at 4°C. DNA was extracted with Chelex 100 per the manufacturer extraction protocol (Bio Rad, United States). Briefly, blots were size cut out from the paper into 1.5 ml microcentrifuge tubes. They were then incubated at 4°C for 30 min in 0.05% saponin phosphate buffered Saline (PBS) and spun at 4,000 rpm for one minute. This was followed by the addition of 150 μ l of 6.7% Chelex resin solution into the microcentrifuge tube containing the spot and incubated at 95°C for 10 min. The tube was then spun for 5 min at 4,000 rpm. To a new microcentrifuge tube was added 500 μ l of the final extract, labelled and stored at 4°C for PCR analysis.

Nested PCR assay. Parasite DNA was then used in nested PCR targeting 18s ssRNA (rRNA) sequences of the Plasmodium parasites (26). In brief the first step involves adding DNA samples (10 μ l) and primers (rPLU5-CTTGTT

GTTGCCTTAACTTC) and rPLU6-TTAAAATTGTTG CAGTTAAAACG) into a 20 μ l PCR master mix for amplification. (It will be helpful to state the concentrations of the constituents of the master mix.). In the second step, 2 μ l of the sample from the first step, was added to primer pairs targeting the different malaria species in five different PCR reactions. Agarose gel electrophoresis was used to analyse the PCR products and GelDoc Go Imaging System used for visualization.

PCR primers used for amplifying the various species DNA

<i>Plasmodium</i> sp.	rPLU5	CTTGTTGTTGCCTTAACTTC
	rPLU6	TTAAAATTGTTGCAGTTAAACG
<i>P. falciparum</i>	rFAL1	TTAAACTGGTTTGGGAAAACCAAATATATT
	rFAL2	ACACAATGAACTCAATCATGACTACCCGTC
<i>P. vivax</i>	rVIV1	CGCTTCTAGCTTAATCCACATAACTGATAC
	rVIV2	ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA
<i>P. ovale</i>	rOVA1	ATCTCTTTTGCTATTTTTTTATGATTGGAGA
	rOVA2	GGAAAAGGACACATTAATGTATCCTAATG
<i>P. malariae</i>	rMAL1	ATAACATAGTTGTACGTTAAGAATAACCGC
	rMAL2	AAAATTCCCATGCATAAAAATTATACAAA

Statistical analysis. Data was entered into Excel spreadsheets and descriptive statistics performed for all variables. Relations of blood groups with malaria and haemoglobin phenotype, were determined using χ^2 -test, and regression models. Statistical analyses were performed using R statistical program, version 3.3.3 and Graph prism, P-values <0.05 were considered statistically significant.

Results

Malaria and low birth weight. Prevalence of placental malaria was high in primiparae (23.5%) as compared to (16.2%) in multiparae mothers, though not statically significant ($P=0.03$), it translated into a significantly low Hb ($P=0.02$) in these mothers, who gave birth to smaller babies ($P=0.01$). Also, the bed-net usage was slightly higher among placental malaria negative mothers 55.6% as compared to 46.5% in mother with placental malaria (Table I).

Blood group o primiparous women are protected from placental malaria. There was no association between any of the blood group types and risk of PM among the pregnant women ($P=0.23$, OR: 1.59, 95% CI, and 0.81-3.13). But when participants were stratified by parity, women with blood group O and who are primiparous, had an increased risk of placenta malaria ($P=0.04$, OR: 2.85, 95% CI, 1.12-9.01) as compared

Table I. Background information.

Variable	All women (n=221)	PM + (n=43)	PM- (n=178)	P-value
Primipara	110 (49.8)	25 (23.0)	85 (77.0)	0.03
Secondipara	46 (20.8)	10 (30.0)	36 (70.0)	
Multipara	65 (29.4)	8 (12.3)	57 (87.6)	
ITN	133 (51.1)	20 (46.5)	99 (55.6)	0.03
Hb (g/dl)	12.2	10.2	12.7	0.02
LBW (Kg)	3.2	2.7	3.3	0.01

Variables between male compare using Mann-Whitney U Test. Values in brackets represent percentage or ranges where applicable. Significant P-values are in italics ($P \leq 0.05$). PM-, placental malaria negative women; PM + placental malaria positive women. ITN, Insecticide treated bed-net; LBW, Live born weight.

Table II. Association of blood groups with placenta malaria.

Parity	PCR testing Placental malaria type	Maternal parameters				P-value
		Blood group	Number	OR	95% CI	
All	PM+	Group O	25	1.59	0.81-3.13	0.23
		Other groups	18			
Primiparae	PM-	Group O	83	1.95	2.12-5.01	0.04 ^a
		Other groups	95			
	PM+	Group O	20			
		Other groups	5			
Multiparae	PM-	Group O	47	1.91	0.74-5.40	0.30
		Other groups	38			
	PM+	Group O	11			
		Other groups	7			
	PM-	Group O	42			
		Other groups	51			

^aUnadjusted OR; primiparous women of blood group O were compared with those with other-blood groups, PM-, placenta malaria.

with those of non-group O. However, there was no observed risk in PM in multiparous women ($P=0.30$, OR: 1.91, 95% CI, 0.74-5.40) (Table II).

Sickle cell not a risk of placenta malaria. The association between sickle cell trait and the risk of peripheral and placenta malaria was investigated by comparing normal haemoglobin (HbAA) and sickle cell trait (HbAS, HbSC and HbSS), using the prevalence of malaria parasitaemia quantified by PCR (Table III). Placental malaria prevalence among women with sickle cell trait (25.8%) was compared with those with HbAA (20.4%), and none of these groups were protected from PM ($P=0.84$, OR: 0.92, 95% CI, 0.43-1.99), nor risk of peripheral malaria ($P=0.61$, OR: 0.79, 95% CI, 0.29-1.94) between the two groups.

Women of blood group O with HbAA phenotype had higher odds of PM, compared with those of non-group O with HbAA, but this was not significant ($P=0.07$, OR: 2.12, 95% CI; 0.92-4.66). And women of blood group O with sickle cell trait phenotype, also had a higher odds of PM compared

with those of non-group O with same trait, but again, not significant ($P=1.00$, OR: 1.03, 95% CI; 0.26-4.10). Primiparous women of group O and HbAA phenotype also had increased odds ($P=0.62$, OR: 1.32, 95% CI; 0.47-3.6) when compared with those with other blood groups with the same phenotype, though again without significant differences. The odds of PM were similar among primiparous women of group O with sickle trait and those of other blood groups with sickle trait ($P=1$, OR: 0.92, 95% CI; 0.15-5.44). Therefore, blood group in combination with haemoglobin phenotype did not increase nor reduce the risk of placental malaria in the two groups (Table IV).

Discussion

This is the first time the risk of placental malaria in the presence of ABO and sickle trait is investigated in pregnant women in a malaria endemic region, Ghana. In this current study primiparous women of other-blood groups (A, B, AB), had a reduced risk of active PM infections when compared with their

Table III. Sickle cell trait and the risk of peripheral malaria.

Sample type	PCR testing Malaria parasitaemia	Maternal parameters				
		Hb genotype	Number	OR	95% CI	P-value
Peripheral	Infection no infection	HbAA	17	0.79	0.29-1.94	0.61
		Sickle trait	7			
		HbAA	150			
		Sickle trait	47			
Placental	Infection No infection	HbAA	32	0.92	0.43-1.99	0.84
		Sickle trait	11			
		HbAA	135			
		Sickle trait	43			

Unadjusted OR; women with sickle cell trait compared with those with HbAA.

Table IV. Hemoglobin phenotype and Blood group as co-factors and Risk of placental malaria.

Parity	PCR testing Placental malaria type	Maternal parameters					
		Blood group	HbAA	Sickle	OR	95% CI	P-value
All	PM+	Group O	19	7	2.12 ^α	0.96-4.66	0.07
		Other groups	13	4	1.03 ^β	0.26-4.10	1.00
Primiparous	PM-	Group O	55	27	1.32 ^γ	0.47-3.67	0.62
		Other groups	80	16			
	PM+	Group O	13	3			
		Other groups	8	3			
Multiparous	PM-	Group O	32	13	0.92 ^δ	0.15-5.44	1.00
		Other groups	26	12			
	PM+	Group O	7	3	3.43 ^ε	0.92-12.8	0.09
		Other groups	4	2			
	PM-	Group O	26	11	0.95 ^λ	0.13-7.23	1.00
		Other groups	5	17			

α, unadjusted OR; women with placental infection and HbAA and of blood group O, compared with those with placental infection and HbAA, but of non-blood group O. β, unadjusted OR; women with placental infection and sickle trait and of blood group O compared with those with placental infection and sickle trait, but of non-blood group O. γ, unadjusted OR; primiparous women with placental infection and HbAA and of blood group O compared with primiparous women with placental infection and HbAA, but of non-blood group O. δ, unadjusted OR; Primiparous women with placental infection and sickle trait and of blood group O compared primiparous women with placental infection and sickle trait, but of non-blood group O. ε, unadjusted OR; multiparous women with placental infection and HbAA and of blood group O compared with multiparous women with placental infection and HbAA, but of non-blood group O. λ, unadjusted OR; multiparous women with placental infection and sickle trait and of blood group O compared multiparous women with placental infection and sickle trait, but of non-blood group O. PM-, placenta malaria.

counterparts with group O. This observation was absent in multiparous women. A similar finding was reported in Sudan, in which pregnant women of non-blood group O were at a lower risk of both active and past PM infections (27). However, in that study multiparous women were also protected. Other studies conducted in the Gambia and Malawi reported a higher risk of active PM in primiparous women, with some reporting protection in multiparous women of blood group O (21,28). It is well established that, non-pregnant individuals of group O are protected from severe malaria disease (29-31) due to

the fact that infected RBCs of blood group O have a reduced ability of rosetting with uninfected erythrocytes (31). This suggests that blood group O can only reduce malaria severity, but not symptomatic and asymptomatic infections, which are implicated in pregnancy associated malaria (32-34). Thus, pregnant women of blood group O may not be prone to severe malaria, but this might not translate into placental malaria protection. During rosetting, iRBCs prefers binding to blood group A1, with least preference for group O (31). And by inference, in a non-blood group O pregnant woman, rosetting will

reduce the chances of iRBCs reaching the microvasculature of the syncytiotrophoblasts, since many of these iRBCs would be clustered by uninfected RBCs and trapped in the intervillous space. This may reduce the chances of an iRBC sequestering in the placenta, thus the relative protection observed in this group. The basis for these assumptions will however need to be further investigated. The possible reason why this observation was not seen among multiparous women in our study may be due to immunity from antibodies (IgG) accumulated from previous exposure to VAR2CSA antigens, which is absent in primiparous women. On the part of haemoglobin phenotypes, previous studies reported HbAS ability to disrupt binding of infected RBCs to microvascular endothelium (35-37). And since infected RBCs (iRBCs) bind to placenta tissue using VAR2CSA (38,39), a disruption of this binding could protect pregnant women from placental malaria. These are the basis on which this study was designed, to investigate the potential effect of disrupting iRBCs attachment to cell surfaces by sickle cell traits and its potential protective effect against PM. But our study could not find any potential protection from HbAS and other sickle cell trait against malaria among women delivery in Ghana.

Sickle cell traits might fail to protect against placental malaria due to the fact that PfEMP1 expression on HbAS iRBC surface is variable and irregular (41). Therefore, HbAS might only restrict the expression of some specific PfEMP1 variants, which might not be sufficient to prevent VAR2CSA binding. It was again observed by Fairhurst *et al* that not all haemoglobin CC cells inhibited malaria parasite replication (40), which suggests that, the degree of protection will depend on the number of these effective (those capable of inhibiting parasite replication) cells in the individual's blood. Also, the relatively lower flow conditions of the intervillous space might promote VAR2CSA binding (15). VAR2CSA is the only specific ligand with high affinity for CSA, which suggests that even in the presence of a limited expression of VAR2CSA on iRBC surface, binding to CSA is still possible (41). And finally, when blood group type and haemoglobin phenotype were considered as co-factors in a pregnant woman, no association was observed between the risk of PM and these factors. Even when pregnant women were grouped by parity, there was still no any association. The protectiveness of non-blood group O against placental malaria in primiparous women, was neutralized when haemoglobin phenotype was considered as a co-factor. This observation may in part be due to the sample size, which was: diluted: when the women were sub-grouped into participants of one blood group phenotype with or without a sickle trait.

Conclusion

These findings indicate that, non-blood O primiparae mothers are protected against placental malaria. Though, it is accepted that primiparae women are very susceptible to placenta malaria, those with non-blood O are protected.

Acknowledgements

Thank you to all participants in this study. We are also grateful to the Hohoe Municipal Hospital staff, especially midwives

and Nurses of the Hospital Labour ward. Also, our gratitude goes to Shelter Gordor, Rukiya Laryea and other members of the University Of Health School of Public Health Clinical Laboratory. We also appreciate, John Tetteh, Sophia Ampah, Jones Amponsah and Eric Kyei-Baafour of the Immunology Department, NMIMR for their technical support, and the University of Ghana's Malaria Centre of Excellence.

Funding

Arnold Togiwe Luuse, was supported by a Ph.D. fellowship from the World Bank African Centres of Excellence Grant (ACE02-WACCBIP: Awandare).

Authors' contributions

ATL and BG conceived and designed the study., BG supervised the work. ATL collected data and laboratory analysis of the study. HA, MAM and ARM assisted in the experiment and data analysis. ATL, MAM, ARM and HA wrote the paper. All authors read and approved the final manuscript.

Consent for publication

The authors have read and agreed to the content of this manuscript and its publication upon acceptance.

Conflict of interest statement

The authors declare that they have no conflict of interests.

XXXXX XXXXX

References

1. Newman RD, Hailemariam A, Jimma D, Degifie A, Kebede D, Rietveld AE, Nahlen BL, Barnwell JW, Steketee RW and Parise ME: Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic year. *J Infect Dis* 187: 1765-1772, 2003.
2. Menéndez C, Bardají A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, Macete E, Berenguera A, David C, Dobaño C, *et al*: A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. *PLoS One* 3: e1934, 2008.
3. Luxemburger C, McGready R, Kham A, Morison L, Cho T, Chongsuphajaisiddhi T, White NJ and Nosten F: Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission. *Am J Epidemiol* 154: 459-465, 2001.
4. Bang SW and Lee SS: The factors affecting pregnancy outcomes in the second trimester pregnant women. *Nutr Res Pract* 3: 134-140, 2009.
5. Chua CLL, Hasang W, Rogerson SJ and Teo A: Poor Birth Outcomes in Malaria in Pregnancy: Recent insights into mechanisms and prevention approaches. *Front Immunol* 12: 621382, 2021.
6. Orish VN, Onyeabor OS, Boampong JN, Aforakwah R, Nwaefuna E and Iriemenam NC: Adolescent pregnancy and the risk of *Plasmodium falciparum* malaria and anaemia-a pilot study from Sekondi-Takoradi metropolis, Ghana. *Acta Trop* 123: 244-248, 2012.
7. Brabin B: An assessment of low birthweight risk in primiparae as an indicator of malaria control in pregnancy. *Int J Epidemiol* 20: 276-283, 1991.
8. Rogerson SJ, Mwapasa V and Meshnick SR: Malaria in Pregnancy: Linking immunity and pathogenesis to prevention. *Am J Trop Med Hyg* 77 (6 Suppl): S14-S22, 2007.

9. Salanti A, Dahlbäck M, Turner L, Nielsen MA, Barfod L, Magistrado P, Jensen AT, Lavstsen T, Ofori MF, Marsh K, *et al*: Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria. *J Exp Med* 200; 1197-1203, 2004.
10. Duffy PE and Fried M: Antibodies that inhibit plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. *Infect Immun* 71: 6620-6623, 2003.
11. Sappenfield E, Jamieson DJ and Kourtis AP: Pregnancy and susceptibility to infectious diseases. *Infect Dis Obstet Gynecol* 2013: 752852, 2013.
12. Walter PR, Garin Y and Blot P: Placental pathologic changes in malaria: A histologic and ultrastructural study. *Am J Pathol* 109: 330-342, 1982.
13. Guyatt HL and Snow RW: Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. *Clin Microbiol Rev* 17: 760-769, 2004.
14. Taylor SM, Parobek CM and Fairhurst RM: Haemoglobinopathies and the clinical epidemiology of malaria: A systematic review and meta-analysis. *Lancet Infect Dis* 12: 457-468, 2012.
15. Taylor SM, Cerami C and Fairhurst RM: Hemoglobinopathies: Slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. *PLoS Pathog* 9: e1003327, 2013.
16. Williams TN, Mwangi TW, Roberts DJ, Alexander ND, Weatherall DJ, Wambua S, Kortok M, Snow RW and Marsh K: An immune basis for malaria protection by the sickle cell trait. *PLoS Med* 2: e128, 2005.
17. Amodu OK, Olaniyan SA, Adeyemo AA, Troye-Blomberg M, Olumese PE and Omotade OO: Association of the sickle cell trait and the ABO blood group with clinical severity of malaria in southwest Nigeria. *Acta Trop* 123: 72-77, 2012.
18. Amoako N, Asante KP, Adjei G, Awandare GA, Bimi L and Owusu-Agyei S: Associations between red cell polymorphisms and Plasmodium falciparum infection in the middle belt of Ghana. *PLoS One* 9: e112868, 2014.
19. Patel JC, Mwapa V, Kalilani L, Ter Kuile FO, Khairallah C, Thwai KL, Meshnick SR and Taylor SM: Absence of association between sickle trait hemoglobin and placental malaria outcomes. *Am J Trop Med Hyg* 94: 1002-1007, 2016.
20. Afoakwa R, Aubyn E, Prah J, Nwaefuna EK and Boampong JN: Relative susceptibilities of ABO blood groups to plasmodium falciparum malaria in Ghana. *Adv Hematol* 2016: 5368793, 2016.
21. Senga E, Loscertales MP, Makwakwa KE, Liomba GN, Dzamala C, Kazembe PN and Brabin BJ: ABO blood group phenotypes influence parity specific immunity to Plasmodium falciparum malaria in Malawian women. *Malar J* 6: 102, 2007.
22. Wolofsky KT, Ayi K, Branch DR, Hult AK, Olsson ML, Liles WC, Cserti-Gazdewich CM and Kain KC: ABO Blood Groups Influence Macrophage-mediated Phagocytosis of Plasmodium falciparum-infected Erythrocytes. *PLoS Pathog* 8: e1002942, 2012.
23. Tadesse H and Tadesse K: Assessing the association of severe malaria infection and ABO blood groups in northwestern Ethiopia. *J Vector Borne Dis* 50: 292-296, 2013.
24. Zerihun T, Degarege A and Erko B: Association of ABO blood group and Plasmodium falciparum malaria in Dore Bafeno Area, Southern Ethiopia. *Asian Pac J Trop Biomed* 1: 289-294, 2011.
25. Kweku M, Ofori M, Takramah W, Axame WK, Owusu R, Parbey P, Adjuik M and Tarkang E: Prevalence of malaria and anaemia among pregnant women attending Antenatal Care Clinic in the Hohoe Municipality of Ghana. *Int J Nurs Didact* 7: 21-30, 2017.
26. Perandin F, Manca N, Calderaro A, Piccolo G, Galati L, Ricci L, Medici MC, Arcangeletti MC, Snounou G, Dettori G and Chezzi C: Development of a Real-Time PCR assay for detection of plasmodium falciparum, plasmodium vivax, and plasmodium ovale for routine clinical diagnosis. *J Clin Microbiol* 42: 1214-1219, 2004.
27. Adam I, Babiker S, Mohammed AA, Salih MM, Prins MH and Zaki ZM: ABO blood group system and placental malaria in an area of unstable malaria transmission in eastern Sudan. *Malar J* 6: 110, 2007.
28. Loscertales MP and Brabin BJ: ABO phenotypes and malaria related outcomes in mothers and babies in The Gambia: A role for histo-blood groups in placental malaria? *Malar J* 5: 72, 2006.
29. Nasr A, Eltoum M, Yassin A and ElGhazali G: Blood group O protects against complicated Plasmodium falciparum malaria by the mechanism of inducing high levels of anti-malarial IgG antibodies. *Saudi J Health Sci* 16, 2012, doi:10.4103/2278-0521.94979.
30. Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Koné A, Diallo DA, Raza A, Kai O, Marsh K, *et al*: Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. *Proc Natl Acad Sci USA* 104: 17471-17476, 2007.
31. Vigan-Womas I, Guillotte M, Juillerat A, Hessel A, Raynal B, England P, Cohen JH, Bertrand O, Peyrard T, Bentley GA, *et al*: Structural Basis for the ABO Blood-Group dependence of plasmodium falciparum rosetting. *PLoS Pathog* 8: e1002781, 2012.
32. Carmona-Fonseca J and Arango EM: Asymptomatic plasmodial infection in pregnant women: A global scenario. *J Vector Borne Dis* 54: 201-206, 2017.
33. Nega D, Dana D, Tefera T and Eshetu T: Prevalence and predictors of asymptomatic malaria parasitemia among pregnant women in the rural surroundings of arbaminch town, south ethiopia. *PLoS One* 10: e0123630, 2015.
34. Tuikue Ndam N, Torniyigah B, Dossou AY, Escriviou G, Nielsen MA, Salanti A, Issifou S, Massougboji A, Chippaux JP and Deloron P: Persistent plasmodium falciparum infection in women with an intent to become pregnant as a risk factor for Pregnancy-associated malaria. *Clin Infect Dis* 67: 1890-1896, 2018.
35. Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakité SA, Arie T, Krause MA, Guindo A, Tubman A, Fujioka H, *et al*: Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. *Proc Natl Acad Sci USA* 105: 991-996, 2008.
36. Fairhurst RM, Fujioka H, Hayton K, Collins KF and Wellems TE: Aberrant development of Plasmodium falciparum in hemoglobin CC red cells: Implications for the malaria protective effect of the homozygous state. *Blood* 101: 3309-3315, 2003.
37. Fairhurst RM, Baruch DI, Brittain NJ, Ostera GR, Wallach JS, Hoang HL, Hayton K, Guindo A, Makobongo MO, Schwartz OM, *et al*: Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. *Nature* 435: 1117-1121, 2005.
38. Brabin BJ, Romagosa C, Abdelgalil S, Menéndez C, Verhoeff FH, McGready R, Fletcher KA, Owens S, D'Alessandro U, Nosten F, *et al*: The sick placenta-the role of malaria. *Placenta* 25: 359-378, 2004.
39. Taylor SM, Messina JP, Hand CC, Juliano JJ, Muwonga J, Tshefu AK, Atua B, Emch M and Meshnick SR: Molecular malaria epidemiology: Mapping and burden estimates for the democratic republic of the congo, 2007. *PLoS One* 6: e16420, 2011.
40. Wang Y and Zhao S: Vascular Biology of the Placenta. In *Integrated Systems Physiology: From Molecules to Function to Disease*. San Rafael (CA), Morgan & Claypool Life Sciences, 2010. Accessed: Nov. 17, 2019. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK53247/>
41. Srivastava A, Gangnard S, Round A, Dechavanne S, Juillerat A, Raynal B, Faure G, Baron B, Ramboarina S, Singh SK, *et al*: Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA. *Proc Natl Acad Sci USA* 107: 4884-4889, 2010.